IMPLEMENTATION OF THE 
AMENDMENTS 
TO APHIS’ NEPA REGULATIONS 
(CATEGORICAL EXCLUSIONS)

BYRON RIPPKE
DIRECTOR, CENTER FOR VETERINARY BIOLOGICS
U.S. DEPARTMENT OF AGRICULTURE
ANIMAL AND PLANT HEALTH INSPECTION SERVICE
VETERINARY SERVICES
OCT 2018
Regulatory Authorities

- 1913 Virus-Serum-Toxin Act (VSTA)
- 1969 National Environmental Policy Act (NEPA)
- 1985 Food Security Act: intrastate, export commerce
- 1995 APHIS’ NEPA Procedures (7CFR Part 372)
  - Replication competent biotech products undergo an environmental assessment per NEPA
- 2018 revision to APHIS’ Implementing Procedures for NEPA
  - Categorical exclusions may apply to live biotech products
Risk Assessment for Live Biotech Vaccines
To Identify Hazards - Unchanged by NEPA Revision

- Examine genotypic + phenotypic stability *in vitro* + in target animals (backpassage/reversion to virulence – VSM 800.201)
- Evaluate zoonotic potential, any changes in tissue tropism or host range
- Assess shed/spread capabilities + effect of overdosing
- Consider recombination potential + consequences
- Assess survivability in environment, target + nontarget animals
Risk Analysis: Assessment, Characterization, Communication, Management

- Risk review by CVB of proposed field trials
  - Environmental assessment (EA) for any live vaccine’s effects on animal safety, public health, or the physical environment
  - The firm submits a Risk Analysis (RA) to CVB + a CBI-redacted version

- NEPA compliance for field safety trial
  - Environmental impact statement (EIS) needed?
  - Decision: significant impact on animals, humans, the environment? input from SMEs - EA or EIS? So far: > 50 EAs, no EIS – all FONSI.
  - Alternative actions are evaluated; any mitigation is identified
  - Action is taken to mitigate possible risk, e.g. restriction to only government use for wildlife vaccines
  - The public is notified of possible risk by Federal Register Notice
Federal Register (FR) Process for Live Biotechnology-Derived Vaccines  
(Not Done if Categorical Exclusion Applies)

- CVB provides the FR Notice, EA, + FONSI (public documents) to the firm for review, then sends the FR Notice, CBI- RA, + EA to Riverdale for agency + departmental review
  - PPD/RAD, OGC, CVB, OA, MRPBS/OSEC, DA (signs docket)
  - Announcement in FR of pending field trials and tentative Finding of No Significant Impact (FONSI)
  - Placement of the CVB-prepared Environmental Assessment and firm’s CBI-redacted Risk Analysis in the FR docket
  - Public comment period, minimum 30 days required
  - If no significant issues arise: signed FONSI, approval of field trials
Review of the Final Rule

- Published in the Federal Register on 5/24/2018
  “Categorical exclusions” (372.5(c)): where testing +/-or monitoring has shown no significant adverse impact on the human environment
  - Less time + resources for redundant studies
  - Benefit to industry, APHIS, + the consumer

Applicable to viable, recombinant, biotech-derived vaccines; but not applicable to diagnostic, inactivated, allergenic, or antibody products

Following publication of the final rule, CVB posted a draft VS Memo with guidelines; comments incorporated, now waiting on DA’s signature
Revision to APHIS’ Implementing Procedures for NEPA

- Categorical exclusion to the FR process for safe, well-characterized vectors or recombinants if no adverse impacts to the environment

- Some potential candidates: fowlpox/other pox virus, canarypox, HVT, adenovirus vectors (although bacterial vectors may also be considered)

- New types or scientifically controversial biotech vaccines will go through the FR process at least once; even a potential CatX’d vector may have a unique circumstance that makes it unacceptable for CatX

- Provisions made for rapid response to emergencies
NEPA Provisions

- An EA or EIS will be prepared for the FR process if there is a higher degree of novelty or uncertainty regarding vaccine safety or potentially hazardous use
  - An EA is prepared for actions with limited scope + potential effect

- **CatX actions could include:**
  - New GE’d vaccines or existing vaccines given to new species if given in a controlled + limited manner, where impacts can be predicted;
  - Vaccination trials designed to limit interaction with similar animals, where controls are used that mitigate potential risk;
  - Authorization to field test unlicensed GE’d vaccines

- ** Exceptions for CatX:** when the biologic is shown to be unsafe, is used in a substantially different way, or involves new species or novel modifications that raise new issues
Implementation of Categorical Exclusions

- What data needed to show a product can be CatX’d?
  - Case-by-case basis: e.g., change of insert without significant effect on performance of the vaccine + insert is nontoxic, non-allergenic

- If one firm has multiple products licensed, would it count for other products from that firm?
  - If same or very similar vector and manufacturing process
  - If change in primers, promoters, insertion size, etc. not significant
  - If same product type? – e.g. all influenza products? Not required

- Other firms using same or similar vector?
  - Need their own well-characterized products, or a technology transfer
Questions?